Alphatec (ATEC) Hits New 1-Year High at $4.35

Alphatec Holdings Inc (NASDAQ:ATEC) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $4.35 and last traded at $4.36, with a volume of 5632 shares changing hands. The stock had previously closed at $4.12.

A number of equities research analysts recently issued reports on ATEC shares. HC Wainwright set a $4.00 target price on shares of Alphatec and gave the company a “buy” rating in a report on Tuesday, February 26th. Zacks Investment Research downgraded shares of Alphatec from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

The firm has a market cap of $193.05 million, a PE ratio of -7.72 and a beta of 1.52. The company has a debt-to-equity ratio of 4.79, a quick ratio of 1.53 and a current ratio of 2.31.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, May 9th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). Alphatec had a negative net margin of 42.16% and a negative return on equity of 156.32%. The company had revenue of $24.56 million during the quarter, compared to the consensus estimate of $24.00 million. As a group, analysts forecast that Alphatec Holdings Inc will post -0.62 EPS for the current fiscal year.

In other Alphatec news, Director Evan Bakst acquired 20,566 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was bought at an average cost of $2.59 per share, for a total transaction of $53,265.94. Following the completion of the purchase, the director now directly owns 726,912 shares in the company, valued at $1,882,702.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kelli Mari Howell acquired 100,000 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were acquired at an average price of $2.59 per share, with a total value of $259,000.00. The disclosure for this purchase can be found here. 44.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Beacon Pointe Wealth Advisors LLC purchased a new stake in Alphatec during the fourth quarter worth approximately $36,000. Bernzott Capital Advisors purchased a new stake in Alphatec during the first quarter worth approximately $45,000. Suntrust Banks Inc. purchased a new stake in Alphatec during the fourth quarter worth approximately $58,000. Raymond James Financial Services Advisors Inc. grew its stake in Alphatec by 49.2% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock worth $67,000 after buying an additional 9,579 shares during the period. Finally, BlueCrest Capital Management Ltd purchased a new stake in Alphatec during the first quarter worth approximately $91,000. Institutional investors own 18.04% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thestockobserver.com/2019/05/16/alphatec-atec-hits-new-1-year-high-at-4-35.html.

Alphatec Company Profile (NASDAQ:ATEC)

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Read More: What is a resistance level?

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.